A hip-fracture study linked vaginal estrogen with perioperative UTIs. Understand the findings, infection-history differences and questions for clinical care.
In an October 14, 2026 release, The Menopause Society reported an association between vaginal-estrogen use and urinary tract infections around hip-fracture surgery. The findings came from research led by Dr. Jocelyn Wittstein of Duke Health. The Society said the results were scheduled for presentation at its 2026 Annual Meeting in San Diego.
The Society’s report raises a focused question about infection risk in postmenopausal hip-fracture patients. For readers familiar with vaginal estrogen through discussions of menopause or recurrent urinary infections, the surgical setting is an important part of the story.
According to The Menopause Society, the study included 375 postmenopausal women treated for hip fracture. Researchers compared infection outcomes according to whether participants reported using vaginal estrogen around the time of surgery.
The treatment-use figures were:
That treatment history matters because the report was largely examining use that preceded the operation. It was not simply describing a treatment first introduced during surgical care.
“Perioperative” means around the time of surgery. It is worth keeping that wording intact when reading the findings rather than assuming the researchers counted only infections that began after the operation.
The researchers also considered age and a history of recurrent urinary tract infections in their statistical models. Those comparisons help explain the reported association. They do not make this study a trial of a new infection-prevention strategy.
The Menopause Society reported that 94 participants experienced at least one perioperative urinary tract infection, or UTI. The report also listed 28 participants with a UTI before surgery.
A history of repeated infections was another important feature of the sample. In total, 56 participants had a history of recurrent UTIs. That history was more common among vaginal-estrogen users than among non-users: 36.36% versus 12.90%.
In the unadjusted analysis, vaginal-estrogen use was associated with increased perioperative UTI risk. After adjustment for age and recurrent-UTI history, vaginal-estrogen use remained associated with higher odds of a perioperative UTI. Recurrent-UTI history was also associated with higher odds in those models.
These results concern the likelihood of infection within this study population. They are not a measure of how commonly vaginal estrogen is used across all postmenopausal women.
The research also examined outcomes beyond urinary infections. Secondary coverage of the same findings reported no significant association between vaginal-estrogen use and emergency-department visits, hospital readmission or mortality within a year after surgery.
That distinction keeps the findings specific. A report about a UTI association should not be rewritten as a finding that vaginal estrogen was associated with every type of hip-fracture complication.
The evidence described in the release is observational. It reports how treatment use and outcomes occurred together rather than establishing that vaginal estrogen caused the infections. Several features determine how much weight the finding can carry.
Women using vaginal estrogen were more likely to have a history of recurrent UTIs. That creates an interpretation problem: a treatment may be concentrated among people who already have a greater likelihood of the outcome being studied.
The researchers adjusted for age and recurrent-UTI history. Statistical adjustment addresses the factors included in a model, but it does not establish that the groups were otherwise comparable. The reported association therefore remains a question for further investigation rather than a demonstrated treatment effect.
The Society’s release does not provide odds ratios or confidence intervals. It also omits p-values and detailed study-design information. Without those details, readers cannot assess the size and precision of the reported association from the release alone.
The exposed subgroup was small. The available report also does not identify a peer-reviewed journal publication. These are preliminary findings shared through a meeting-related announcement rather than a fully described journal paper.
Wittstein suggested that incomplete adherence and the concentration of treatment use among patients already at higher UTI risk might help explain the results. Those were possible explanations offered by the lead author. The study report did not establish that either explanation caused the observed pattern.
The participants were postmenopausal women treated for hip fracture. The findings do not establish what happens in other surgical settings or among people using vaginal estrogen without a fracture.
Likewise, the absence of significant associations with the other reported outcomes is not proof that treatment has no effect on them. The study also does not establish that stopping vaginal estrogen would reduce perioperative UTI risk or that using it prevents UTIs in this surgical setting.
The Menopause Society’s release describes vaginal estrogen as a treatment used to help prevent recurrent UTIs in postmenopausal and perimenopausal women. That established use is the context for the researchers’ question. They were examining whether preoperative use was associated with fewer infections around hip-fracture surgery.
Wittstein said the team was surprised that preoperative use did not reduce perioperative UTIs in this population. She called for research into different delivery methods. That is a research proposal, not a recommendation that readers switch products or methods.
The Society’s medical director, Dr. Stephanie Faubion, also emphasized the importance of users’ greater likelihood of having a recurrent-infection history. She called for further work on whether vaginal estrogen could reduce perioperative UTI risk.
The distinction between the treatment’s broader purpose and the outcome measured here is central. Preventing recurrent infections during menopause and preventing infections around hip-fracture surgery are related questions. They are not interchangeable research questions.
This update therefore belongs alongside existing evidence rather than replacing it. The authors’ response was to ask for more investigation into the surgical setting, not to present the association as a reason to abandon vaginal estrogen generally.
For readers approaching the topic through sexual comfort or hormonal change, broader educational context remains useful. Sexential’s guide to estrogen and sexual wellbeing across adulthood addresses the wider topic beyond this particular surgical outcome.
The practical value of this report is a more focused conversation with a qualified clinician. That conversation can bring together the reason for treatment, a history of recurrent infections and the circumstances of any planned surgery. Those details are more useful than treating the headline as a stand-alone treatment decision.
The report supports questions such as:
These questions do not assume that a person needs a different treatment. They help separate the issue being studied from the individual decision that belongs in clinical care.
For someone concerned mainly about menopause-related comfort or intimacy, naming that concern clearly can keep the discussion focused. A study measuring perioperative infections should not take the place of a conversation about what the person is experiencing and what they want help understanding.
Related reading on vaginal and vulvar wellbeing after menopause can provide a separate starting point for those broader questions. Keeping the topics distinct allows both the surgical finding and the person’s original concern to receive appropriate attention.
There is no need to turn a research update into a personal verdict about treatment. A clinician can review the finding alongside the individual’s symptoms and care history rather than asking a single association to answer every question.
Sexual wellbeing deserves careful evidence and a calm conversation.
A surgical infection finding can attract attention far beyond the patients studied, leaving readers to separate a focused research question from broader concerns about menopause and intimacy. Sexential places hormones and sexual function within the everyday lives of midlife adults through calm educational writing rather than individual treatment advice.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
